The aim of this recent cVAD Registry analysis
was to assess survival differences between men and women supported with Impella 2.5 in the setting of acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). The article concludes that early initiation of hemodynamic support prior to PCI with Impella 2.5, in the setting of AMI complicated by CS, was associated with a greater survival benefit to hospital discharge in women compared to men. This despite a higher predicted risk of mortality and a greater revascularization failure rate for women.
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information